These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 14514729

  • 1. Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation.
    Bao L, Zhou J, Holers VM, Quigg RJ.
    J Am Soc Nephrol; 2003 Oct; 14(10):2516-25. PubMed ID: 14514729
    [Abstract] [Full Text] [Related]

  • 2. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice.
    Bao L, Haas M, Kraus DM, Hack BK, Rakstang JK, Holers VM, Quigg RJ.
    J Am Soc Nephrol; 2003 Mar; 14(3):670-9. PubMed ID: 12595503
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Alteration in kidney glucose and amino acids are implicated in renal pathology in MRL/lpr mice.
    Alexander JJ, Zwingmann C, Jacob A, Quigg R.
    Biochim Biophys Acta; 2007 Oct; 1772(10):1143-9. PubMed ID: 17942282
    [Abstract] [Full Text] [Related]

  • 5. Complement-dependent apoptosis and inflammatory gene changes in murine lupus cerebritis.
    Alexander JJ, Jacob A, Bao L, Macdonald RL, Quigg RJ.
    J Immunol; 2005 Dec 15; 175(12):8312-9. PubMed ID: 16339572
    [Abstract] [Full Text] [Related]

  • 6. Absence of functional alternative complement pathway alleviates lupus cerebritis.
    Alexander JJ, Jacob A, Vezina P, Sekine H, Gilkeson GS, Quigg RJ.
    Eur J Immunol; 2007 Jun 15; 37(6):1691-701. PubMed ID: 17523212
    [Abstract] [Full Text] [Related]

  • 7. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice.
    Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, Alexander JJ, Anderson RK, Culhane K, Holers VM, Quigg RJ.
    J Immunol; 2002 Apr 01; 168(7):3601-7. PubMed ID: 11907125
    [Abstract] [Full Text] [Related]

  • 8. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice.
    Sekine H, Reilly CM, Molano ID, Garnier G, Circolo A, Ruiz P, Holers VM, Boackle SA, Gilkeson GS.
    J Immunol; 2001 May 15; 166(10):6444-51. PubMed ID: 11342671
    [Abstract] [Full Text] [Related]

  • 9. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis.
    Alexander JJ, Bao L, Jacob A, Kraus DM, Holers VM, Quigg RJ.
    Biochim Biophys Acta; 2003 Nov 20; 1639(3):169-76. PubMed ID: 14636948
    [Abstract] [Full Text] [Related]

  • 10. The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice.
    Shi Y, Yao W, Sun L, Li G, Liu H, Ding P, Hu W, Xu H.
    BMC Nephrol; 2019 Nov 21; 20(1):424. PubMed ID: 31752725
    [Abstract] [Full Text] [Related]

  • 11. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B.
    Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, Boackle SA, Colten HR, Gilkeson GS.
    J Immunol; 2000 Jan 15; 164(2):786-94. PubMed ID: 10623824
    [Abstract] [Full Text] [Related]

  • 12. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
    Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson GS, Tomlinson S.
    Arthritis Rheum; 2011 Apr 15; 63(4):1076-85. PubMed ID: 21452327
    [Abstract] [Full Text] [Related]

  • 13. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice.
    Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, Gilkeson GS.
    Kidney Int; 2004 Jan 15; 65(1):129-38. PubMed ID: 14675043
    [Abstract] [Full Text] [Related]

  • 14. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology.
    Kikawada E, Lenda DM, Kelley VR.
    J Immunol; 2003 Apr 01; 170(7):3915-25. PubMed ID: 12646661
    [Abstract] [Full Text] [Related]

  • 15. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice.
    Anders HJ, Belemezova E, Eis V, Segerer S, Vielhauer V, Perez de Lema G, Kretzler M, Cohen CD, Frink M, Horuk R, Hudkins KL, Alpers CE, Mampaso F, Schlöndorff D.
    J Am Soc Nephrol; 2004 Jun 01; 15(6):1504-13. PubMed ID: 15153561
    [Abstract] [Full Text] [Related]

  • 16. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
    Yao L, Chen HP, Ma Q.
    Immunol Lett; 2014 Sep 01; 161(1):76-80. PubMed ID: 24837470
    [Abstract] [Full Text] [Related]

  • 17. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice.
    Lenda DM, Stanley ER, Kelley VR.
    J Immunol; 2004 Oct 01; 173(7):4744-54. PubMed ID: 15383612
    [Abstract] [Full Text] [Related]

  • 18. Involvement of infiltrating macrophage-derived activin A in the progression of renal damage in MRL-lpr mice.
    Kadiombo AT, Maeshima A, Kayakabe K, Ikeuchi H, Sakairi T, Kaneko Y, Hiromura K, Nojima Y.
    Am J Physiol Renal Physiol; 2017 Feb 01; 312(2):F297-F304. PubMed ID: 27881396
    [Abstract] [Full Text] [Related]

  • 19. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease.
    Pérez de Lema G, Lucio-Cazaña FJ, Molina A, Luckow B, Schmid H, de Wit C, Moreno-Manzano V, Banas B, Mampaso F, Schlöndorff D.
    Kidney Int; 2004 Sep 01; 66(3):1018-28. PubMed ID: 15327395
    [Abstract] [Full Text] [Related]

  • 20. Unrestricted C3 activation occurs in Crry-deficient kidneys and rapidly leads to chronic renal failure.
    Bao L, Wang Y, Chang A, Minto AW, Zhou J, Kang H, Haas M, Quigg RJ.
    J Am Soc Nephrol; 2007 Mar 01; 18(3):811-22. PubMed ID: 17229915
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.